Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
基本信息
- 批准号:10084654
- 负责人:
- 金额:$ 33.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-21 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:12 year old15 year oldAddressAdultAfricaAfrica South of the SaharaAnogenital venereal wartsAntibodiesAntibody titer measurementAnusBedside TestingsBirthBloodCancer BurdenCancer EtiologyCervicalCervical Cancer ScreeningCessation of lifeClinical ResearchColposcopyCountryDataDoseEffectivenessEnrollmentEnzyme-Linked Immunosorbent AssayFutureGardasilGeneral PopulationGenerationsGenotypeGoalsHIVHIV InfectionsHIV SeronegativityHPV-High RiskHealth PlanningHigh PrevalenceHigh Risk WomanHuman Papilloma Virus VaccinationHuman Papilloma Virus VaccineHuman Papilloma Virus-Related Malignant NeoplasmHuman PapillomavirusHuman papilloma virus infectionHuman papillomavirus 11Human papillomavirus 16Human papillomavirus 18Human papillomavirus 6Immune responseImmunityImmunocompetentImpairmentInfectionLateralLocalesLong-Term EffectsLongitudinal StudiesMalignant NeoplasmsMalignant Vaginal NeoplasmMalignant neoplasm of anusMalignant neoplasm of cervix uteriMalignant neoplasm of penisMalignant neoplasm of vulvaMeasuresMedicalMedicineMethodsMilitary HospitalsNatural HistoryObservational StudyOralOutcomePerformancePopulationPopulation StudyPrevalencePrevention strategyProspective StudiesProspective cohort studyPublic HealthReportingResearchResolutionResourcesRiskRisk FactorsRwandaSafetySamplingSchoolsSecondary toSensitivity and SpecificitySpecimenSurrogate EndpointTarget PopulationsTestingUniversitiesVaccinatedVaccinationVirus-like particleVisitWomanWorld Health Organizationagedbasecarcinogenicitycervical cancer preventioncervicovaginalcervicovaginal microbiomechronic infectioncohortcollegecomparison groupcostelementary schoolfollow-upgirlsimmunogenicityinnovationmalignant oropharynx neoplasmoral infectionpoint of careprogramsprophylacticprotective effectrare cancerresponsesixth gradevaccine effectivenessvalidation studiesvirtualyoung adultyoung manyoung woman
项目摘要
Abstract:
Cervical cancer is the 4th most common cancer and cause of cancer-related death in women globally; in
many lower-resource settings, especially sub-Saharan Africa (SSA), it is the most common. Virtually all
cervical cancer and precancer are caused by high-risk human papillomavirus (hrHPV). HPV16 causes ~55-
60% and HPV18 causes ~10-15% of cervical cancer while the remaining ~12 HPV types cause the remaining
25-30% of cervical cancer. hrHPV, predominately HPV16, also causes most anal, vulvar, vaginal, and penile
cancers and a significant proportion of oropharyngeal cancers. Prophylactic HPV vaccines have been
developed and have shown to be nearly 100% protective against incident infection and related abnormalities
against the target HPV types in the general population. However, the evidence for the effectiveness of
prophylactic HPV vaccines in women living with human immunodeficiency virus (HIV) (WLWH) is less clear.
HIV infection increases the risk of cervical cancer due to an impaired immune response to HPV.
In 2011, Rwanda, a high-burden cervical cancer country in East Africa that has an HIV prevalence in
adult women of 3.3%, implemented a national HPV vaccination program with Gardasil®, which protects
against HPV16 and HPV18, the two HPV types that cause ~70% of cervical cancer, and HPV6 and HPV11,
the two types that cause ~90% of anogenital warts (HPV6/11/16/18). Their program has achieved >90%
coverage of the target population, primarily girls aged 12 years, annually. The implementation of a highly
successful HPV vaccination program and the high prevalence of HIV, in addition to the research and medical
capacity that Albert Einstein College of Medicine (Einstein) has helped to build at the Rwanda Military Hospital
(RMH) and University of Rwanda (UR), makes Rwanda the ideal locale to study the long-term effects of HPV
vaccination in WLWH.
To answer questions about HPV vaccine effectiveness and immunity in Rwanda WLWH, collaborators
at Einstein, RMH, and UR will conduct an observational study of WLWH and HIV-negative (HIV[-]) women who
did (birth cohorts 1997 and later) and WLWH did not receive HPV vaccination (birth cohorts before 1997). We
will compare the cervical, anal, and oral prevalent and 6-month persistent HPV6/11/16/18 infections in 757
HPV-vaccinated WLWH to those in 757 unvaccinated WLWH. We will also compare the HPV immune
response in 548 HPV-vaccinated WLWH to 548 HPV-vaccinated HIV[-] women and the impact of switching
from 3 doses to 2 doses of Gardasil in 2015. We also will validate a low-cost, simple point-of-care test for
HPV16 antibodies as method to verify/determine HPV vaccination status. Finally, we will investigate the risk
factors, including the cervicovaginal microbiome, for HPV persistence in WLWH. Our (long-term) goal is to
establish a cohort of WLWH in whom we can examine the long-term effectiveness of HPV vaccination in
WLWH now and in the future. This contribution is significant as it will establish the population effectiveness of
HPV vaccination in WLWH living in SSA, the women at the highest risk of cervical cancer, for which there is a
dearth of evidence. The proposed research is innovative as it leverages and expands the local research and
medical capacity in Rwanda to examine one of the critically unanswered questions about HPV vaccine
effectiveness in the context of the World Health Organization call for the global control of cervical cancer.
摘要:
宫颈癌是全球第四大常见癌症和与癌症相关的死亡原因;
许多资源较低的地区,特别是撒哈拉以南非洲(SSA),这是最常见的。几乎所有的
宫颈癌和癌前病变是由高危人乳头瘤病毒(HrHPV)引起的。HPV16引起~55-
60%的宫颈癌和HPV18导致约10-15%的宫颈癌,其余约12种HPV型导致其余的宫颈癌
25%-30%的宫颈癌。HrHPV,主要是HPV16,也导致大多数肛门、外阴、阴道和阴茎
癌症和相当大比例的口咽癌。预防性HPV疫苗已经被
已开发并已显示出对意外感染和相关异常几乎100%的保护
与普通人群中的目标HPV类型进行比较。然而,证明其有效性的证据
携带人类免疫缺陷病毒(WLWH)的妇女是否接种预防性HPV疫苗尚不清楚。
由于对HPV的免疫反应受损,艾滋病毒感染会增加患宫颈癌的风险。
2011年,卢旺达,一个东非高负担的宫颈癌国家,艾滋病毒在
3.3%的成年妇女使用Gardasil®实施了全国HPV疫苗接种计划,该计划可保护
对于HPV16和HPV18这两种导致70%的宫颈癌的HPV类型,以及HPV6和HPV11,
引起约90%的肛门生殖器疣的两种类型(HPV6/11/16/18)。他们的计划已经达到了90%
每年覆盖目标人群,主要是12岁的女孩。实施一项高度的
成功的HPV疫苗接种计划和艾滋病毒的高流行率,以及研究和医疗
爱因斯坦医学院(爱因斯坦)在卢旺达军事医院帮助建立的能力
(RMH)和卢旺达大学(UR)的合作,使卢旺达成为研究HPV长期影响的理想场所
WLWH的疫苗接种。
为了回答有关卢旺达WLWH HPV疫苗有效性和免疫力的问题,合作者
在爱因斯坦,RMH和UR将对WLWH和HIV阴性(HIV[-])女性进行一项观察性研究
DID(1997年及以后的出生队列)和WLWH没有接受HPV疫苗接种(1997年之前的出生队列)。我们
将比较757例宫颈、肛门、口腔和6个月持续HPV6/11/16/18感染情况
对757例未接种HPV的WLWH进行HPV免疫接种。我们还将比较人乳头瘤病毒免疫
548名HPV接种者WLWH对548名HPV接种者的应答及转换的影响
2015年,Gardasil从3剂增加到2剂。我们还将验证低成本、简单的医疗点测试
HPV16抗体作为验证/确定HPV疫苗接种情况的方法。最后,我们将调查风险
HPV在WLWH中持续存在的因素,包括宫颈阴道微生物群。我们的(长期)目标是
建立WLWH队列,我们可以在队列中检查HPV疫苗接种的长期效果
WLWH现在和未来。这一贡献意义重大,因为它将确立
在WLWH接种HPV疫苗居住在SSA,是宫颈癌风险最高的妇女,对此有
缺乏证据。拟议的研究具有创新性,因为它利用和扩展了当地的研究和
卢旺达检查关于HPV疫苗的一个严重悬而未决的问题的医疗能力
在世界卫生组织呼吁全球控制宫颈癌的背景下取得成效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathryn M. Anastos其他文献
Kathryn M. Anastos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathryn M. Anastos', 18)}}的其他基金
Rwanda CASCADE Clinical Trials Site for cervical cancer prevention
卢旺达 CASCADE 宫颈癌预防临床试验基地
- 批准号:
10757692 - 财政年份:2023
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
- 批准号:
10414093 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/ Malignancies
爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟
- 批准号:
10267220 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
- 批准号:
10267222 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
- 批准号:
10267223 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
- 批准号:
10084653 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
- 批准号:
10084655 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/ Malignancies
爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟
- 批准号:
10654706 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV Malignancies
爱因斯坦/卢旺达/刚果民主共和国 HIV/HPV 恶性肿瘤研究联盟
- 批准号:
10654712 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/Malignancies
爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟
- 批准号:
10654699 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
相似海外基金
Research on the legal position of 'U-25 people'-autonomy at the 15-year-old, help to the 25-five?years-old
“U-25人”的法律地位研究——15岁的自主权,对25岁五岁的帮助
- 批准号:
20530068 - 财政年份:2008
- 资助金额:
$ 33.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
EFFECT OF HYDRATION STATUS ON BASKETBALL PERFORMANCE: 12-15 YEAR-OLD BOYS
水分状态对篮球表现的影响:12-15 岁男孩
- 批准号:
7378538 - 财政年份:2006
- 资助金额:
$ 33.37万 - 项目类别:
EFFECT OF HYDRATION STATUS ON BASKETBALL PERFORMANCE: 12-15 YEAR-OLD BOYS
水分状态对篮球表现的影响:12-15 岁男孩
- 批准号:
7203587 - 财政年份:2005
- 资助金额:
$ 33.37万 - 项目类别:
Replacement of a 15 Year-Old X-ray Microanalysis Unit
更换已有 15 年历史的 X 射线微量分析装置
- 批准号:
9313813 - 财政年份:1994
- 资助金额:
$ 33.37万 - 项目类别:
Standard Grant